Skin and Joints Podcast copertina

Skin and Joints Podcast

Skin and Joints Podcast

Di: Mimi Tran Aaron Sihota Danny Mansour Ashley Yip Julia Tan Touraj Khosravi Anastasiya Muntyanu
Ascolta gratuitamente

A national multidisciplinary masterclass exploring inflammatory skin and joint related conditions led by healthcare experts from across Canada and the US.2026 Skin and Joints Podcast Disturbo fisico e malattia Igiene e vita sana Scienza Scienze biologiche
Episodi
  • Cross Border Talk with Raj Chovatiya and Melinda Gooderham: Hands On, Gloves Off

    Cross Border Talk with Raj Chovatiya and Melinda Gooderham: Hands On, Gloves Off
    Jun 22 2026
    🎙️🇨🇦🇺🇸. Hands On, Gloves Off: Cross-Border Talk on Atopic Hand Eczema We’re coming to you from the heart of Music City, Nashville 🎸 — but don’t worry, this Cross-Border Talk is not about trade, tariffs, or hockey rivalries. This time, it’s all hands on deck. ✋🇨🇦🇺🇸 In this episode of the Skin and Joints Podcast from RAD 2026, our Cross-Border Dermatologist Faculty Dr. Raj Chovatiya from the U.S. joins Canadian favourite Dr. Melinda Gooderham for a lively, practical, and focused conversation on atopic hand eczema, chronic hand eczema, and fresh week 32 data exploring tralokinumab in this challenging and high-burden body site. Hands may represent a small body surface area, but they carry an outsized burden. They are exposed, functional, visible, constantly irritated, and central to work, hobbies, caregiving, gardening, handshakes, procedures, and everyday life. In other words: when the hands are flaring, patients are not just uncomfortable — they are often functionally sidelined. 🧤🌱 This episode goes beyond the usual did the trial hit the endpoint discussion and digs into the real-world so what? You’ll hear how the week 32 data may help frame expectations, why some patients may need more time before being labelled non-responders, how itch and pain improvements matter alongside clearance, and how shared decision-making can turn clinical trial endpoints into conversations patients actually understand. 📊🩺 The discussion also gets practical on where tralokinumab may fit alongside emerging topical options like delgocitinib, how to think about atopic hand eczema versus broader chronic hand eczema phenotypes, and why a back to basics approach remains timeless advice when patients are not responding as expected. 🔍 From Nashville notes to Monday morning clinic, this Cross-Border Talk offers a hands-on look at atopic hand eczema — with just enough clinical soil turned over to leave you wanting the full episode. 🎙️✋ Learning Objectives 🎯 After listening to this episode, listeners will be able to: Describe the clinical and functional burden of atopic hand eczema✋, including why hands represent a uniquely challenging and high-impact treatment site despite limited body surface area involvement.Summarize key elements of the week 32 tralokinumab data in atopic hand eczema📊, including trial design, patient population, efficacy signals, symptom outcomes, and tolerability considerations.Interpret week 16 versus week 32 response data through a real-world clinical lens🕒, including how to counsel partial responders and avoid prematurely labelling treatment as failure.Integrate patient-reported outcomes into treatment decision-making🗣️, particularly itch, pain, function, visibility, and the patient’s ability to return to meaningful daily activities.Differentiate treatment considerations for atopic hand eczema versus broader chronic hand eczema🧩, including when topical, systemic, or combination strategies may be appropriate.Apply practical clinic-based reassessment strategies for patients with persistent hand eczema🔍, including evaluation for irritant contact dermatitis, allergic contact dermatitis, occupational exposures, and ongoing trigger management. ABOUT Dr. Raj Chovatiya, MD, PhD, MSCI Associate Professor | Rosalind Franklin University of Medicine and Science Chicago Medical School Founder and Director | Center for Medical Dermatology + Immunology Research Chicago, USA Raj Chovatiya, MD, PhD, MSCI is Associate Professor at Rosalind Franklin University of Medicine and Science Chicago Medical School and Founder and Director of the Center for Medical Dermatology + Immunology Research in Chicago, Illinois. His clinical and research focus includes the intersection of cutaneous immunology and inflammatory disease. He received his MD and PhD in immunology from Yale and completed his residency, postdoctoral research fellowship, and MS in Clinical Investigation at Northwestern University where he also served as Chief Resident. Dr. Chovatiya has a particular interest in optimizing patient-centered care, understanding chronic disease burden especially in understudied inflammatory diseases, exploring health and social disparities, and improving care across diverse skin types. He has published numerous abstracts and manuscripts and has been nationally and internationally recognized for his contributions as a clinician, educator, researcher, and leader. ABOUT Dr.Melinda Gooderham, MD, FRCPC ( Dermatology) Toronto, ON Melinda Gooderham MD MSc FRCPC Dr. Gooderham is a Dermatologist and Medical Director at the SKiN Centre for Dermatology and an Investigator with Probity Medical Research. She is an Assistant Professor at Queens University and a Consultant Physician at the Peterborough Regional Health Centre. She is a fellow of the Royal College of Physicians and Surgeons of Canada. Dr. Gooderham has been the principal ...
    Mostra di più Mostra meno
    28 min
  • The Switch Pitch: Biosimilars In Real World HS Care PART 1

    The Switch Pitch: Biosimilars In Real World HS Care PART 1
    Jun 18 2026
    🎙️ PART 1: Real-World Biosimilar Care in HS with Dr. Lauren Lam and Dr. Marni Wiseman HS has officially entered the Skin and Joints chat — and it did not come quietly. In this special Part 1 episode, we welcome back two Skin and Joints Podcast Faculty favourites, dermatologists Dr. Lauren Lam and Dr. Marni Wiseman, for a practical, candid, and refreshingly real-world conversation on hidradenitis suppurativa, biologics, and the evolving role of biosimilars in Canadian care. From delayed diagnosis and cumulative life-course impact to biologic timing, patient expectations, injection burden, access barriers, and the art of asking, “How sick of this are you?” — this episode digs into the clinical realities that do not always fit neatly into trial endpoints. Dr. Lam and Dr. Wiseman share frontline insights on why HS is uniquely challenging, why earlier intervention may change the patient journey, and how biosimilars are reshaping access, dosing conversations, and practical treatment decisions. Expect clinical pearls, a few myth-busting moments, and clinic hot tips you can actually use — from identifying the right referral pathway, to setting realistic goals, minimizing injection burden, considering dose optimization, and translating trial endpoints into real-life wins for patients. Also discussed: tennis dreams, cottage shade, citrate-free formulations, the joy of one injection instead of two, and why HS care is rarely a solo sport. 🎾🌿💉 Learning Objectives After listening to this episode, learners should be able to: Describe why hidradenitis suppurativa is uniquely challenging to manage compared with other chronic inflammatory skin diseases, including the role of delayed diagnosis, comorbidities, surgery, pain, drainage, scarring, and quality-of-life burden.Identify real-world factors that influence biologic initiation in HS, particularly in moderate disease, including patient-reported impact, flare burden, treatment goals, and the importance of earlier intervention when clinically appropriate.Explain the current relevance of adalimumab biosimilars in Canadian HS care, including access, reimbursement, compassionate support, patient counselling, and confidence in biosimilar efficacy and safety.Apply practical counselling strategies for patients starting or switching to biosimilar therapy, including how to discuss expectations, injection burden, pain, formulation differences, and meaningful patient-centred outcomes.Recognize clinic-ready strategies to optimize HS care, including referral tips, patient-centred goal setting, realistic timelines for improvement, combination therapy considerations, and individualized dose optimization in patients with persistent disease activity. #SkinAndJointsPodcast #HidradenitisSuppurativa #HSAwareness #Biosimilars #Adalimumab #Dermatology #RheumDerm #InflammatoryDisease #RealWorldEvidence #PatientCenteredCare #BiologicTherapy #CanadianDermatology #MedicalPodcast #ClinicianEducation #ClinicHotTips #AccessToCare Episode supported by Celltrion Canada. ABOUT Dr. Lauren Lam BScH, MD, FRCPC ​​Medical, Surgical & Cosmetic Dermatologist CALGARY, AB Dr. Lam is the Vice President of the Canadian Hidradenitis Suppurativa Foundation and a Canadian Board Certified Dermatologist subspecializing in Hidradenitis Suppurativa Deroofing Procedures. She runs a weekly deroofing clinic in Calgary, Alberta, and has done 1500+ cases to date. Besides collaborating on global HS projects, her other favourite endeavours include being an international explorer, culinary enthusiast and aunt to 5 dogs. ABOUT Dr. Marni C. Wiseman MD FRCPC DABD Associate Professor, Section Head Dermatology University of Manitoba Director, SKiNWISE DERMATOLOGY and Wiseman Dermatology Research Dr. Marni C. Wiseman began her Dermatology practice in Winnipeg, Manitoba in 2001.She is an Associate Professor and Section Head of Dermatology at the Faculty of Medicine at the University of Manitoba. Dr. Wiseman is the Medical Director of SKiNWISE DERMATOLOGY, where she conducts her private medical practice. Dr. Wiseman’s areas of clinical and research interest include inflammatory disease: psoriasis, atopic dermatitis, hidradenitis suppuritiva, vitiligo, alopecia areata, urticaria, and acne vulgaris. Dr Wiseman is Principal Investigator at Wiseman Dermatology Research and has participated in hundreds of clinical trials and registry studies. Dr. Wiseman is a frequent lecturer at meetings and congresses nationally and internationally and is extensively published in areas of inflammatory skin disease, photodermatosis, and cutaneous malignancy. Dr. Wiseman is a supervisor and mentor for medical students and residents, conducts regular rural/remote outreach clinics, has significant volunteer involvement with the Canadian Dermatology Association, the Canadian Hidradenitis Suppuritiva Foundation, and is an editor of the Journal of Cutaneous Medicine and Surgery. EPISODE SUPPORTED BY ...
    Mostra di più Mostra meno
    24 min
  • The Great Atopic Dermatitis Dose Debate: Escalate, De-escalate, or Hold Steady?

    The Great Atopic Dermatitis Dose Debate: Escalate, De-escalate, or Hold Steady?
    Jun 3 2026
    🎙️The Great Dose Debate: Escalate, De-escalate, or Hold Steady?

    In this final episode of our AAD 2026 atopic dermatitis post-game poster series, we’re joined by dermatologist Dr. Julien Ringuet from Quebec City for a practical, no-fluff breakdown of the JADE REAL analysis — and what flexible abrocitinib dosing may actually mean when Monday morning clinic rolls around.

    Because in real life, patients do not always follow a tidy trial algorithm. Symptoms flare, itch keeps people up, adherence shifts, priorities change, and sometimes the “right” dose is less of a fixed destination and more of a GPS recalculating in real time. 🧭

    Dr. Ringuet walks us through the clinical “so what” behind dose escalation and de-escalation, explaining why moving from 100 mg to 200 mg — or stepping down from 200 mg to 100 mg — should not automatically be seen as failure, overtreatment, or backpedalling.

    Instead, flexible dosing may be part of a thoughtful, shared decision-making strategy that better reflects the messy, dynamic reality of moderate-to-severe atopic dermatitis care.

    We cover how early reassessment, patient-reported outcomes, itch, sleep, EASI trends, payer flexibility, and treat-to-target thinking all fit into the bigger picture. And yes, we also discuss the real-world art of knowing when to push, when to pause, and when to test the waters with a lower dose. 🌊

    ✨ Learning Objectives

    By the end of this episode, listeners should be able to:

    1. Describe how the JADE REAL study design reflects real-world clinical decision-making in moderate-to-severe atopic dermatitis.
    2. Explain why dose escalation and de-escalation with abrocitinib may represent intentional treatment optimization rather than treatment failure.
    3. Identify practical clinical scenarios where starting at 100 mg versus 200 mg may be appropriate.
    4. Discuss how early follow-up, patient-reported outcomes, itch, sleep, and quality-of-life measures can help guide dose adjustment decisions.
    5. Recognize key limitations of open-label, real-world evidence when translating study findings into clinical practice.
    6. Apply a treat-and-adjust approach to atopic dermatitis management using shared decision-making and individualized treatment goals.

    💡 Key Takeaway

    Flexible dosing is not a loophole — it is real-world dermatology. The win is not finding one perfect pathway for every patient; it is learning how to reassess early, individualize thoughtfully, and adjust with purpose. 🩺

    🎧 Tune in for practical pearls, real-world nuance, and Dr. Ringuet’s post-game analysis on what these data may mean for dermatologists managing AD in everyday practice.

    #SkinAndJointsPodcast #AAD2026 #AtopicDermatitis #EczemaCare #Dermatology #PatientReportedOutcomes #JAKInhibitors #abrocitinib #DermatologyEducation #MedicalEducation #HCPeducation #TreatToTarget #InflammatorySkinDisease #ClinicalData #DermTwitter #MedEd #Vodcast #PodcastEpisode #AADDenver #JAK #JAKinhibitor

    ABOUT Dr. Julien Ringuet

    Dermatologist, Quebec City, QC

    Dr Ringuet is a board certified dermatologist who practices in Quebec City as the principal investigator at the Centre de Recherche Dermatologique de Québec (CRDQ).


    He completed his medical training (MD) and his post graduate studies in dermatology form Laval University as well as a master in experimental medicine (MSc.) in the field of skin bioengineering at the Laboratoire d’Organogénèse Expérimentale de l’Université Laval (LOEX/CMDGT).


    Dr Ringuet and his team of the CRDQ are allowing patient access to quality and innovative clinical research focused on alopecia areata, atopic dermatitis, psoriasis and its variants and vitiligo.

    Supported by an IME Grant from PFIZER.



    📻www.skinandjoints.ca

    ✉️info@skinandjoints.ca
    Mostra di più Mostra meno
    20 min
adbl_web_anon_alc_button_suppression_t1
Ancora nessuna recensione